Scholarlink

<p>Transcranial magneto-acoustic stimulation (TMAS) is a noninvasive neuromodulation technique that has demonstrated benefits for neuroplasticity in Parkinson’s disease (PD), yet its underlying mechanisms remain inadequately understood. This study aimed to investigate how TMAS affects dysfunction and synaptic-plasticity impairments in the corticostriatal pathway in a subacute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mouse model. The results indicated that TMAS was associated with reduced presynaptic glutamate release and with improved N-methyl-D-aspartate receptor (NMDAR)-mediated responses. It also enhanced D1 dopamine receptor-dependent basal synaptic transmission and partially restored bidirectional corticostriatal synaptic plasticity. Furthermore, TMAS tended to normalize the distribution of spine subtypes, improve motor deficits, reduce dopaminergic neuron loss, and decrease aberrant α-synuclein expression. Transcriptomic and enrichment analyses further suggested a coordinated modulation of gene programs related to synaptic organization, ion homeostasis, and immune responses. These findings support TMAS as a promising noninvasive neuromodulation approach in the MPTP mouse model. TMAS attenuated excessive glutamatergic transmission and improved corticostriatal synaptic plasticity, providing a testable mechanistic framework for future studies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Transcranial magneto-acoustic stimulation improves corticostriatal transmission in direct medium spiny neurons and rescues neuroplasticity of Parkinson’s disease model mice

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月1日

查看全文
  • Yihao Xu,
  • Shuai Zhang,
  • Jinrui Mi,
  • Xiaochao Lu,
  • Yuchen An,
  • Jizhou Liu,
  • Jiaqi Sun,
  • Yanbin Wang,
  • Guizhi Xu

摘要

Transcranial magneto-acoustic stimulation (TMAS) is a noninvasive neuromodulation technique that has demonstrated benefits for neuroplasticity in Parkinson’s disease (PD), yet its underlying mechanisms remain inadequately understood. This study aimed to investigate how TMAS affects dysfunction and synaptic-plasticity impairments in the corticostriatal pathway in a subacute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mouse model. The results indicated that TMAS was associated with reduced presynaptic glutamate release and with improved N-methyl-D-aspartate receptor (NMDAR)-mediated responses. It also enhanced D1 dopamine receptor-dependent basal synaptic transmission and partially restored bidirectional corticostriatal synaptic plasticity. Furthermore, TMAS tended to normalize the distribution of spine subtypes, improve motor deficits, reduce dopaminergic neuron loss, and decrease aberrant α-synuclein expression. Transcriptomic and enrichment analyses further suggested a coordinated modulation of gene programs related to synaptic organization, ion homeostasis, and immune responses. These findings support TMAS as a promising noninvasive neuromodulation approach in the MPTP mouse model. TMAS attenuated excessive glutamatergic transmission and improved corticostriatal synaptic plasticity, providing a testable mechanistic framework for future studies.